Skip to main content
. Author manuscript; available in PMC: 2021 Nov 26.
Published in final edited form as: Sci Transl Med. 2021 May 26;13(595):eabe8226. doi: 10.1126/scitranslmed.abe8226

Figure 1. H6PD and regulation of glucocorticoid metabolism with enzalutamide resistance..

Figure 1.

(A) Effects of Enz treatment on H6PD, GR and 11β-HSD2 in the LAPC4 CRPC model as assessed by immunoblot. (B) NADPH generation in LAPC4 cells with enz treatment. NADPH was assessed using a bioluminescence assay in endoplasmic reticulum extracted from control and enz-treated cells. (C) H6PD and 11β-HSD2 protein in tissues from enz-treated patients with prostate cancer. Bar graphs represent band intensity; 3 paired tissues from 3 patients with prostate cancer were analyzed. (D) Effects of enz on H6PD and 11β-HSD2 protein with ex vivo treatment of 12 clinical tissues from prostate cancer patients. For all panels unless otherwise noted, error bars represent the SEM, and p values were calculated using unpaired 2-tailed t-tests.